Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy
Clinical Pharmacology & Therapeutics September 30, 2024 Andreas Halman, Rachel Conyers, Claire Moore et al. 13 citations
Genetic variations in drug-metabolizing enzymes, particularly cytochrome P450, can influence the intensity of acute effects from psychedelics like LSD and ibogaine, suggesting that dose reductions may be appropriate for CYP2D6 poor metabolizers. Preclinical evidence also indicates that CYP2D6 metabolizer status might alter psychedelic experiences with 5-MeO-DMT and psilocybin when combined with monoamine oxidase inhibitors. Although evidence is limited, especially for pharmacodynamics, pharmacogenomic testing warrants further investigation to potentially improve safety and personalize psychedelic-assisted therapies for psychiatric conditions.